July 1, 2008Open Access

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

EML4-ALK is found in the minority of NSCLC. ALK kinase inhibitors alone or in combination may nevertheless be clinically effective treatments for NSCLC patients whose tumors contain EML4-ALK.

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Koivunen et al. (Tue,) studied this question.

synapsesocial.com/papers/69dcc30ed4d0de07d11339c8 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-08-0168

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Addiction to Oncogenes--the Achilles Heal of Cancer2002 · 1,734 citations
2Cancer Statistics, 20072007 · 7,473 citations
3Distribution of gamma satellite DNA on the human X and Y chromosomes suggests that it is not required for mitotic centromere function2000 · 13 citations
4Fusion of a Kinase Gene, <i>ALK</i> , to a Nucleolar Protein Gene, <i>NPM</i> , in Non-Hodgkin's Lymphoma1994 · 2,403 citations
5Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies2007 · 928 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper